Aerie Pharmaceuticals Inc

-0.38 (-2.49%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)697.32M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$26.38 Million
Adjusted EPS-$0.69
See more estimates
10-Day MA$15.53
50-Day MA$16.03
200-Day MA$15.70
See more pivots

Aerie Pharmaceuticals Inc Stock, NASDAQ:AERI

4301 Emperor Boulevard, Suite 400, Durham, North Carolina 27703
United States of America
Phone: +1.919.237.5300
Number of Employees: 365


Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.